Skip to main content

Table 2 (abstract A59). Components of SLEDAI Present within 30 days of Baseline Visit and at Most Recent Follow Up Visits

From: Proceedings of the 2019 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting

SLEDAI Component Baseline Visit, n=380
n (%)
Most Recent
Follow Up Visit , n=219
n (%)
Seizure 0 0
Psychosis 4 (1%) 0
Organic Brain Syndrome 0 0
Visual Disturbance 4 (1%) 2 (1%)
Cranial Nerve Disorder 0 0
Lupus Headache 11 (3%) 4 (2%)
Cerebrovascular Accident 0 0
Vasculitis 11 (3%) 7 (3%)
Arthritis 61 (16%) 46 (12%)
Myositis 15 (4%) 7 (3%)
Urinary Casts 57 (15%) 18 (8%)
Hematuria 27 (7%) 11 (5%)
Proteinuria 27 (7%) 7 (3%)
Pyuria 23 (6%) 7 (3%)
Rash 80 (21%) 33 (15%)
Alopecia 27 (7%) 7 (3%)
Mucosal Ulcers 30 (8%) 7 (3%)
Pleurisy 4 (1%) 0
Pericarditis 4 (1%) 0
Low Complement 148 (39%) 68 (31%)
Increased DNA Binding 103 (27%) 50 (23%)
Fever 27 (7%) 2 (1%)
Thrombocytopenia 15 (4%) 2 (1%)
Leukopenia 53 (14%) 22 (10%)
  1. IRB approval was via Protocol 00054616 (Duke University)